Short answer
BioAge Labs, Inc. (BIOA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
BioAge Labs, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release attached as Exhibit 99.1, providing the substantive financial details
Item EX-99.1 · Exhibit EX-99.1
- QUELL-CV fully enrolled at approximately 160 participants, with 30 mg, 60 mg, and 90 mg doses; topline data expected Q4 2026
- QUELL-DME Phase 2 dosed its first participant, targeting approximately 180 patients; topline results expected in H2 2027
- APJ obesity program remains on track for first IND submission by year-end 2026, adding a second clinical development catalyst
- Q3 net loss widened to $33.5M, or $0.73 per share, from $20.2M, or $0.56 per share
- Cash, equivalents, and marketable securities totaled approximately $352.3M, supporting operations and capital expenses through 2029 under the current plan
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BioAge Labs, Inc. 8-K filings
Get the next BIOA 8-K as it lands
Follow BIOA for push alerts, or ask the research agent what this filing means.